Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall readout is in line with the Chinese data that drummed up excitement in the ...
AstraZeneca, Gilead get a new challenger as Pyramid deviates from TRK to bag antibody-drug conjugate
Pyramid Biosciences’ current pipeline is built around the kinase TRK. But the biotech has now struck a deal that will take it down a new path, paying $20 million upfront and betting $1 billion in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback